Gilead Sciences (GILD) Stock Lands $7.8B Arcellx Deal — Is This the Buy Opportunity?

TLDR

• Gilead completed its $7.8 billion acquisition of Arcellx on April 28, 2026, gaining full control of anito-cel, a CAR T-cell therapy for multiple myeloma.
• GILD is retesting an 11-year cup base breakout at a pivot of $123.47, with one analyst targeting $173 by year end — a 35% gain.
• The stock is down 8% this month but has gained 22% over the past year; it trades around $128.
• GILD’s RSI has hit 27, making it as oversold as it has been in at least a year, with 200-day SMA support nearby.
• The Arcellx deal is expected to reduce GAAP and non-GAAP 2026 diluted EPS by $5.57–$5.67, but is projected to be accretive from 2028 onward, pending FDA approval.

Gilead Sciences closed its acquisition of Arcellx on April 28, paying $115 per share in cash plus a contingent value right of $5 per share. The total implied equity value at closing came to approximately $7.8 billion.

Gilead Sciences, Inc., GILD

The deal gives Gilead full ownership of anitocabtagene autoleucel, or anito-cel, an investigational BCMA-directed CAR T-cell therapy targeting multiple myeloma. Previously, Gilead and Arcellx operated under a collaboration agreement through Kite, Gilead’s cell therapy unit.

By absorbing Arcellx outright, Gilead eliminates future profit-share payments, milestones, and royalty obligations. That positions the company to move faster on development and commercialization decisions.

The $5 CVR per share becomes payable only if cumulative global net sales of anito-cel hit at least $6 billion from launch through the end of 2029. That’s a meaningful bar, but it reflects confidence in the therapy’s commercial potential.

Cindy Perettie, Gilead’s head of Kite, said the focus now turns to “executing with speed and discipline” as the company prepares to bring anito-cel to patients. Arcellx’s team and its D-Domain BCMA binder technology will integrate into Kite’s manufacturing and regulatory infrastructure.

On the financial side, the transaction is expected to reduce Gilead’s GAAP and non-GAAP 2026 diluted EPS by $5.57 to $5.67. Excluding acquired in-process R&D expenses, the deal is projected to be modestly dilutive in 2026 and 2027, then accretive from 2028 onward — assuming FDA approval of anito-cel.

Arcellx common stock will be delisted from the Nasdaq Global Select Market following the merger’s completion.

Technical Picture

From a chart standpoint, GILD is at an interesting spot. The stock is retesting an 11-year cup base breakout at a pivot level of $123.47 — a pattern that dates back to bearish candlestick signals in June and July 2015.

Longer-term breakouts tend to have higher success rates, which makes this retest worth watching. The stock’s RSI has dropped to 27, a level not seen in at least a year, signaling oversold conditions. The 200-day simple moving average is nearby and has acted as support in both May and October of last year.

GILD has declined in eight of the last 10 weeks, and is down 8% in April alone. Both March and April’s declines came on soft volume, which some technicians view as a constructive sign.

Broader Biotech Context

The SPDR S&P Biotech ETF is up 9% in 2026, bucking weakness in the broader healthcare sector, which is down 7% and the worst-performing of the 11 major S&P sectors. The iShares Biotechnology ETF, where Gilead is the largest holding at nearly 8% of assets, has returned less than 1% year to date.

GILD itself is up 4% year to date and 22% over the past 12 months despite the recent pullback. One technical analyst has set a $173 price target for year end, implying a 35% gain from current levels around $128. The bull case holds as long as the stock stays above $118.

Gilead completed its tender offer for Arcellx on April 28, with tendered shares representing approximately 77.2% of Arcellx’s outstanding stock.

The post Gilead Sciences (GILD) Stock Lands $7.8B Arcellx Deal — Is This the Buy Opportunity? appeared first on CoinCentral.